SERPINA1 and alpha 1-antitrypsin deficiency: Indeed, routine AAT treatment, as afforded to individuals with AAT deficiency (AATD) (77), has been commonplace for over three decades, and clinical evidence points to a reduction in bacterial infections in AAT-treated AATD individuals (76) as well as a lack of rise in tumor development rates.